Open access · CC-BY
via OpenAlex
A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition
Clemens Stockklausner, Simon Raffel, Julia Klermund, Obul Reddy Bandapalli, Fabian Beier, Tim H. Brümmendorf, Friederike Bürger, Sven Wolfgang Sauer, Georg Friedrich Hoffmann, Holger Lorenz, Laura Tagliaferri, Daniel Nowak, Wolf‐Karsten Hofmann, Rebecca Buergermeister, Carolin Kerber
Aging · 2015 · ▲ 17 citations
Genomic instability
Telomere attrition
Deregulated nutrient-sensing
Cellular senescence
Stem-cell exhaustion
Rapamycin / mTOR inhibition
Telomerase activation
Cell culture / in vitro
Yeast
Human
Mouse
In vitro
Abstract
The TERT gene encodes for the reverse transcriptase activity of the telomerase complex and mutations in TERT can lead to dysfunctional telomerase activity resulting in diseases such as dyskeratosis congenita (DKC). Here, we describe a novel TERT mutation at position T1129P leading to DKC with progressive bone marrow (BM) failure in homozygous members of a consanguineous family. BM hematopoietic stem cells (HSCs) of an affected family member were 300-fold reduced associated with a significantly impaired colony forming capacity in vitro and impaired repopulation activity in mouse xenografts. Recent data in yeast suggested improved cellular checkpoint controls by mTOR(definition) inhibition preventing cells with short telomeres or DNA damage from dividing. To evaluate a potential therapeutic option for the patient, we treated her primary skin fibroblasts and BM HSCs with the mTOR inhibitor rapamycin(definition). This led to prolonged survival and decreased levels of senescence(definition) in T1129P mutant fibroblasts. In contrast, the impaired HSC function could not be improved by mTOR inhibition, as colony forming capacity and multilineage engraftment potential in xenotransplanted mice remained severely impaired. Thus, rapamycin treatment did not rescue the compromised stem cell function of TERTT1129P mutant patient HSCs and outlines limitations of a potential DKC therapy based on rapamycin.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.18632/aging.100835
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Stockklausner, C., Raffel, S., Klermund, J., Bandapalli, O.R., Beier, F., Brümmendorf, T.H., Bürger, F., Sauer, S.W., Hoffmann, G.F., Lorenz, H., Tagliaferri, L., Nowak, D., Hofmann, W., Buergermeister, R., Kerber, C., Rausch, T., Korbel, J.O., Luke, B., Trumpp, A., & Kulozik, A.E. (2015). A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition. <em>Aging</em>. https://doi.org/10.18632/aging.100835
Vancouver
Stockklausner C, Raffel S, Klermund J, Bandapalli OR, Beier F, Brümmendorf TH, et al. A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition. Aging. 2015. doi:10.18632/aging.100835.
BibTeX
@article{clemens2015Anovel,
title = {A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition},
author = {Clemens Stockklausner and Simon Raffel and Julia Klermund and Obul Reddy Bandapalli and Fabian Beier and Tim H. Brümmendorf and Friederike Bürger and Sven Wolfgang Sauer and Georg Friedrich Hoffmann and Holger Lorenz and Laura Tagliaferri and Daniel Nowak and Wolf‐Karsten Hofmann and Rebecca Buergermeister and Carolin Kerber and Tobias Rausch and Jan O. Korbel and Brian Luke and Andreas Trumpp and Andreas E. Kulozik},
journal = {Aging},
year = {2015},
doi = {10.18632/aging.100835},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Experimental Dermatology 2009
Open access · OA
Proliferative defects in dyskeratosis congenita skin keratinocytes are corrected by expression of the telomerase reverse transcriptase, TERT, or by activation of endogenous telomerase through expression of papillomavirus E6/E7 or the telomerase RNA component, TERC
Frontiers in aging 2026
Open access · OA
Repurposing MK0873 as a non-covalent hTERT-Targeting compound: a proof of concept study.
Genes & Development 2008
Preprint · OA
Engineered telomere degradation models dyskeratosis congenita
Genes & Development 2004
Preprint · OA
Telomerase- and recombination-independent immortalization of budding yeast
Science-Business eXchange 2008
Open access · OA
Telomerase reverse transcriptase (TERT)
International Journal of Molecular Medicine 2021
Open access · CC-BY